Liraglutide alleviates depression in mice via gut microbiota-endocannabinoid pathway, independent of GLP-1R activation
Background
Glucagon-like peptide-1 receptor (GLP-1R) agonists are widely prescribed for metabolic diseases like type 2 diabetes and obesity. However, their neuropsychiatric effects, particularly on depressive symptoms, remain poorly understood and controversial. While GLP-1R activation is central to their metabolic actions, it's unclear if this mechanism extends to their potential mood-modulating effects, leaving a significant gap in understanding their broader therapeutic potential beyond direct receptor engagement.
Study Design
Researchers investigated liraglutide's antidepressant effects in mice using both pharmacological (e.g., GLP-1R antagonist Exn9 treatment) and genetic (Glp1r-/- mice) approaches. They assessed depression-like behaviors and then explored underlying mechanisms by depleting gut microbiota. Multi-omics analyses were employed to identify specific microbial and metabolic changes. Finally, fecal microbiota transplantation (FMT) from liraglutide-treated mice and colonization with specific bacterial strains were performed to confirm causality.
Results
Liraglutide consistently demonstrated antidepressant efficacy in mice. Crucially, this effect persisted even when GLP-1R was pharmacologically blocked with Exn9 or genetically absent in Glp1r-/- mice, indicating a GLP-1R-independent mechanism. Conversely, gut microbiota depletion completely abolished liraglutide's antidepressant effects, highlighting the microbiota's essential role. Multi-omics analyses revealed that liraglutide significantly increased the abundance of Lactobacillus delbrueckii. This increase, in turn, restored levels of the endocannabinoid 2-arachidonoylglycerol (2-AG). The elevation of 2-AG was found to mediate the antidepressant effects by normalizing excessive neuronal activity in brain regions critical for emotional processing.
Importantly, fecal microbiota transplantation from liraglutide-treated mice or direct colonization with
Lactobacillus delbrueckiialone successfully replicated the antidepressant effects.
Key Findings
- Liraglutide's antidepressant effects in mice are independent of
GLP-1Ractivation. - Gut microbiota depletion abolished liraglutide's antidepressant efficacy.
- Liraglutide increased
Lactobacillus delbrueckiiabundance in the gut. Lactobacillus delbrueckiirestored2-arachidonoylglycerol (2-AG)levels, mediating antidepressant effects.- Fecal microbiota transplantation from liraglutide-treated mice replicated antidepressant effects.
Why It Matters
This study uncovers a groundbreaking, non-canonical mechanism for GLP-1 analogs, suggesting their antidepressant actions are mediated by the gut microbiota and endocannabinoid system, rather than direct GLP-1R activation. This fundamentally shifts our understanding of how GLP-1RAs might impact mood and opens new avenues for depression treatment. Targeting the specific microbiota-endocannabinoid pathway, perhaps through probiotics like Lactobacillus delbrueckii or endocannabinoid modulators, could offer novel therapeutic strategies for depression, potentially as adjuncts to existing GLP-1RA therapies or as standalone interventions.
liraglutide
depression
gut-brain-axis
microbiota
endocannabinoid
preclinical-animal